Kineta Immuno-Oncology has entered into a strategic research collaboration with Pfizer Inc. to develop RIG-I agonist immunotherapies for the treatment of cancer.     The research collaboration and license agreement grants to Pfizer the exclusive rights to KIO’s RIG-I screening platform and related compounds and technologies.  The companies will collaborate to develop and test small molecule agonists that target RIG-I, an innate immunostimulatory pathway that can elicit immunogenic ...